Get the Stockscreener App
17.38
0.70%
0.12
After Hours:
17.38
Xencor Inc stock is traded at $17.38, with a volume of 1.23M.
It is up +0.70% in the last 24 hours and up +31.57% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$17.26
Open:
$17.36
24h Volume:
1.23M
Relative Volume:
1.06
Market Cap:
$1.24B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-6.0138
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
+10.21%
1M Performance:
+31.57%
6M Performance:
+129.59%
1Y Performance:
-31.30%
1-Day Range:
$17.14
$17.80
1-Week Range:
$15.38
$17.80
52-Week Range:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
17.38 | 1.23B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Truist Financial Initiates a Buy Rating on Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Coverage Initiated by Analysts at Truist Financial - MarketBeat
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
DCF Advisers LLC Cuts Stake in Xencor, Inc. $XNCR - MarketBeat
Xencor Shares Surge on Clinical Breakthroughs and Analyst Confidence - Ad-hoc-news.de
Truist Securities Initiates Coverage on Xencor (XNCR) with Buy R - GuruFocus
Truist Securities initiates coverage on Xencor stock with Buy rating By Investing.com - Investing.com Nigeria
Truist Securities initiates coverage on Xencor stock with Buy rating - Investing.com India
Xencor’s XmAb819 Study: A Promising Step in Cancer Treatment - MSN
Primecap Management Co. CA Has $82.75 Million Holdings in Xencor, Inc. $XNCR - MarketBeat
Is Xencor Inc. stock a safe buy before earningsJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Will Xencor Inc. (XE9) stock benefit from commodity supercycleJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
Xencor Shares Show Renewed Promise as Biotech Specialist Stages Recovery - Ad-hoc-news.de
Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor Inc (XE9.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Xencor Inc. (XE9) stock undervalued by metricsWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
Xencor upgraded to Overweight from Underweight at Barclays - MSN
Will Xencor Inc. (XE9) stock hit Wall Street targetsWatch List & Long Hold Capital Preservation Plans - newser.com
Is Xencor Inc. (XE9) stock undervalued historically2025 Volatility Report & Real-Time Market Trend Scan - newser.com
Why analysts remain bullish on Xencor Inc. stockChart Signals & Long-Term Investment Growth Plans - newser.com
Is Xencor Inc. stock attractive for growth ETFs2025 Top Decliners & Community Consensus Trade Signals - newser.com
Should you hold or exit Xencor Inc. now2025 Breakouts & Breakdowns & Precise Buy Zone Tips - newser.com
How Xencor Inc. (XE9) stock benefits from digital adoptionPortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Tick level data insight on Xencor Inc. volatilityJuly 2025 Decliners & Stepwise Swing Trade Plans - newser.com
Can a trend reversal in Xencor Inc. lead to recoveryMarket Movers & Fast Exit Strategy with Risk Control - newser.com
How Xencor Inc. stock compares to growth peersJuly 2025 Retail & Daily Chart Pattern Signals - newser.com
What candlestick patterns are forming on Xencor Inc.Insider Buying & Daily Entry Point Trade Alerts - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Has $231,000 Stock Position in Xencor, Inc. $XNCR - MarketBeat
Why Xencor Inc. stock remains on buy listsDip Buying & Fast Momentum Stock Entry Tips - newser.com
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):